In a groundbreaking development in the field of Otorhinolaryngology, a recent study has unveiled a potential breakthrough in the treatment of acute tonsillopharyngitis, a condition often associated with respiratory viral infections, including COVID-19. As per the findings, gargling with Hydroxymethylquinoxylindioxide solution (antimicrobial agent) in acute tonsillopharyngitis provided rapid pain relief and reduced inflammation severity, promoting quicker and more complete mucous membrane recovery.

Sore throat emerges as the primary symptom of acute tonsillopharyngitis, linked to the aftermath of previous respiratory viral infections. The pathogenesis of these conditions arises from the combined impact of the direct damage caused by viruses and subsequent inflammatory changes in the mucosal epithelium at the infection site. This process occurs in conjunction with alterations in the functions of the regional microbiota, leading to the development of viral-bacterial inflammation surpassing the protective-reparative threshold.

In the treatment of acute tonsillopharyngitis, especially after ruling out Group A beta-hemolytic Streptococcus pyogenes (GABHS) etiology, topical etiotropic drugs are commonly employed. The goal is to achieve a consistent distribution of active ingredients while maximizing additional pharmacological capabilities, such as irrigation-eliminative action and reparative effects.

To establish a robust evidence base regarding the effectiveness of these medications, a prospective observational comparative study was undertaken.

This study utilized cytomorphological approaches (cytomorphometry) in conjunction with the clinical assessment method. Gargling with Hydroxymethylquinoxylindioxide solution (Dioxydin 0.25 mg/ml solution for topical application) demonstrated a swift alleviation of pain and a reduction in the severity of inflammation symptoms. The solution showed the potential to limit the destruction of the epithelium during inflammation, contributing to a more complete and rapid recovery of the damaged mucous membrane.

These findings underscore the clinical significance of Dioxydin in the management of acute tonsillopharyngitis, showcasing its potential as an effective therapeutic option. This research not only offers a promising avenue for the treatment of acute tonsillopharyngitis but also emphasizes the importance of advancing our understanding of respiratory viral infections. Further studies and clinical trials are anticipated to solidify these findings and pave the way for enhanced treatment protocols.